Real-world effectiveness and treatment costs of ceftazidime-avibactam versus colistin-meropenem for ICU-acquired MDR gram-negative infections in liver transplant recipients.
BACKGROUND Multidrug-resistant (MDR) Gram-negative infections remain a threat after liver transplantation, yet comparative treatment data in critically ill recipients are scarce. Therapeutic decisions are complicated by immunosuppression, resistance mechanisms, and antimicrobial toxicity. We evaluated ceftazidime-aviba...